Search Weight Loss Topics:

Page 4«..3456..1020..»

Nov 28

Global Thermal Scanners Market 2020 | Covid-19 Impact Analysis and Industry Forecast Report Till 2027 – Birmingham Alive

The latest market research study aboutGlobalThermal ScannersMarket Research Report 2020-2027focuses on recent and future growth trends related to the business. The report covers several factors such as global distribution, manufacturers, and various regions. The report has summed up industry analysis size, share, application, and statistics associated with the globalThermal Scannersmarket. It explains significant details associated with the demand and supply analysis, market share growth. The insightful research report on the market includes Porters Five Forces Analysis and SWOT Analysis to understand the factors affecting consumer and supplier behavior. The report also estimates comprehensive market revenue along with growth opportunities, market share coupled with product type and application. patterns and the overall volume of the market are also evaluated in the report.

The report reviews the competitive landscape scenario seen among top market players, their company profile, revenue, sales, business tactics, and forecasts market situation. For excellent business growth, companies must take upmarket research report service which has become enough important in todays marketplace. Crucial information and forecast statistics covered in the globalThermal Scannersmarket report will assist both existing and emerging market players with necessary insights to craft long-term strategies as well as maintain business growth during the projected time-period from 2020 to 2027.

NOTE:Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post the COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.


Market segmentation is done on the basis of its present and prospective inclinations. The report covers key statistics on the market status of the globalThermal Scannersmarket manufacturers. This study allows industry stakeholders such as manufacturers and partners, end-users to strategize investments and capitalize on market opportunities. Furthermore, the scope of the growth potential, revenue growth, product range, and pricing factors related to the market are thoroughly assessed. The report analyzes the competitive landscape of the companies and the flow of the global supply and consumption.

Companies operating in the industry:Opgal, Seek Thermal, Leonardo S.p.A., Axis Communications AB, Tonbo Imaging, C-THERMAL, Infratec GmbH, Terabee, AMETEK Land, HGH Infrared Systems, Fluke Corporation, VUMII Imaging, Optotherm, Inc., L3harris Technologies, Inc., FLIR Systems, Inc., Thermoteknix Systems Ltd., Xenics, Testo SE & Co. KGaA, Cox, HGH Infrared Systems, and 3M Scott

Uses of A Product Based On End-Users:

The factors on which the businesses compete within the market are evaluated within the report. This globalThermal Scannersmarket report also presents product specification, manufacturing process, and product cost structure, etc. Production is separated by regions, technology, and applications. The report further covers upstream raw materials, equipment, downstream client survey, marketing channels, industry development trend, and proposals.

Geographically, this report is segmented into several key regions including:

North America, Europe, Asia Pacific, South America, and the Middle East and Africa.

Request forCustomization:

The report sheds light on details about key parameters that will define the commercialization matrix of the globalThermal Scannersmarket. It further elaborates on the driving factors to study their impact on the profit trends of this industry sphere. The study shows the information about the challenges the market will face over the anticipated timeline from 2020 to 2027 and its effect on the market space.


Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (, who will ensure that you get a report that suits your needs.

Contact UsMark

Read more:
Global Thermal Scanners Market 2020 | Covid-19 Impact Analysis and Industry Forecast Report Till 2027 - Birmingham Alive

Nov 24

HGH now offering walk-in psychotherapy services – The Review Newspaper

Access to local mental health services is much faster now due to a new service available from the Mental Health and Addiction Regional Centre and Hawkesbury and District General Hospital (HGH).

The centre is now offering free, walk-in, single-session psychotherapy sessions each Wednesday from 9 a.m. to 3 p.m. at 580 Spence Avenue in Hawkesbury, which is located next to Taco Bell. No appointment is necessary, and clients must be aged 16 or older.

HGH Director of Mental Health and Addictions Genevive Arturi said that the single sessions allow the five therapists on staff to identify the needs of clients and give them strategies to use after. She acknowledged that the approach does not solve all of a clients problems but is meant to meet the need for rapid response. Arturi said that clients in need of more than one session will be directed into the other programs HGH offers.

Canadian Mental Health Association Champlain East Executive Director Joanne Ledoux-Moshonas said that one in 10 Ontario residents has difficulty accessing mental health services.

Arturi said that up to eight clients per day can be seen at the new walk-in service. Telephone appointments can also be arranged by calling 1-844-304-1414.

No situation is too small or to big to access our clinic, said HGH Chief of Staff, Dr. Julie Maranda.

The walk-in psychotherapy clinic at HGH was made possible through at $20,000 donation from the Bell Canada Lets Talk Foundation.

HGH now offering walk-in psychotherapy services - The Review Newspaper

Nov 24

Heartland Group Holdings Limited (NZX: HGH) reassesses the valuation of its investment in HMY – sharechat

Heartland Group Holdings Limited (ASX & NZX: HGH ) advises that it is reassessing the valuation of its equity investment in Harmoney Corp Limited (ASX & NZX: HMY ).

Following the IPO, Heartland owns 8,518,864 ordinary shares in HMY, representing 8.44% of HMYs total shares on issue. Alongside other majority shareholders, employees and directors, Heartland has entered into escrow restrictions prohibiting the disposal of its shareholding until the occurrence of certain events.

Heartland will reassess the fair value of its equity investment in HMY as part of the preparation of its financial results for the six-month period ending 31 December 2020 (HY21). In determining fair value, Heartland will take into consideration the market value of HMY shares alongside a range of other relevant factors, including the escrow restrictions. This may result in an increase in the fair value of the investment.

Heartlands equity investment in HMY is not significant in the context of Heartlands total assets. However, any increase in the fair value of that investment would result in one-off increase to Heartlands net profit after tax (NPAT) for the financial year ended 30 June 2021 (FY21). That increase has not been taken into account in Heartlands forecast NPAT for FY21, which may accordingly need to be revised.

See the link below for more details:

NZX & ASX Release - HGH reassesses value in HMY investment

Source:Heartland Group Holdings Limited

No comments yet

Smartpay Holdings Limited (NZX: SPY) Interim Result Announcement and Half Year ReportGreen Cross Health Limited (NZX: GXH) Reports Half Year Profit of $8.8MFletcher Building Limited (NZX: FBU) Annual Shareholders Meeting Documents and 1H21 GuidanceComvita Limited (NZX: CVT) Reports Strong China Market Sales During 11:11 EventKathmandu Holdings Limited (NZX: KMD) Trading UpdateGoodman Property Trust (NZX: GMT) to Redevelop Strategic Mt Roskill SiteTurners Automotive Group Limited (NZX: TRA) Delivers Robust Earnings Despite COVID DisruptionFisher & Paykel Healthcare Corporation Limited (NZX: FPH) Record Half Year Result: Net Profit Up 86%Stride Property Group (NZX: SPG) Trading Halt of SecuritiesStride Property Ltd & Stride Investment Management Ltd (NZX: SPG) HY21 Interim Results and Capital Raise

See the original post:
Heartland Group Holdings Limited (NZX: HGH) reassesses the valuation of its investment in HMY - sharechat

Nov 24

JAWS and the 2021 Hall of Fame Ballot: Andy Pettitte – FanGraphs

The following article is part of Jay Jaffes ongoing look at the candidates on the BBWAA 2021 Hall of Fame ballot. Originally written for the 2019 election, it has been updated to reflect recent voting results as well as additional research. For a detailed introduction to this years ballot, and other candidates in the series, use the tool above; an introduction to JAWS can be found here. All WAR figures refer to the Baseball-Reference version unless otherwise indicated.

As much as Derek Jeter, Jorge Posada, Mariano Rivera, and Bernie Williams, Andy Pettitte was a pillar of the Joe Torre-era Yankees dynasty. The tall Texan lefty played such a vital role on 13 pinstriped playoff teams and seven pennant winners plus another trip to the World Series during his three-year run with Houston that he holds several major postseason records. In fact, no pitcher ever started more potential series clinchers, both in the World Series and the postseason as a whole.

For as important as Pettitte was to the Core Four (Williams always gets the short end of the stick on that one) that anchored five championships from 1996 to 2009 and to an Astros team that reached its first World Series in 05 he seldom made a case as one of the games top pitchers. High win totals driven by excellent offensive support helped him finish in the top five of his leagues Cy Young voting four times, but only three times did he place among the top 10 in ERA or WAR, and he never ranked higher than sixth in strikeouts. He made just three All-Star teams.

Indeed, Pettitte was more plow horse than racehorse. A sinker- and cutter-driven groundballer whose pickoff move was legendary, he was a championship-level innings-eater, a grinder (his word) rather than a dominator, a pitcher whose strong work ethic, mental preparation, and focus visually exemplified by his peering in for the sign from the catcher with eyes barely visible underneath the brim of his cap compensated for his lack of dazzling stuff. Ten times he made at least 32 starts, a mark thats tied for seventh in the post-1994 strike era. Within that span, his total of 10 200-inning seasons is tied for fourth, and his 13 seasons of qualifying for the ERA title with an ERA+ of 100 or better is tied for first with two other lefties, Mark Buehrle (a newcomer to this years ballot) and CC Sabathia. He had his ups and downs in the postseason, but only once during his 18-year career (2004, when he underwent season-ending elbow surgery) was he unavailable to pitch once his team made the playoffs.

Even given Pettittes 256 career wins, he takes a back seat to two other starters on the ballot (Roger Clemens and Curt Schilling) who were better at missing bats and preventing runs, and who also had plenty of postseason success. Both of those pitchers have reasons why voters might exclude them from their ballots even while finding them statistically qualified, and the same is true for Pettitte, who was named in the 2007 Mitchell Report for having used human growth hormone to recover from an elbow injury. Between those dents and dings and the additional presence of both Roy Halladay and Mike Mussina, Pettitte received just 9.9% in his 2019 ballot debut, and even on a less crowded slate, his share only increased to 11.3% last year. He seems unlikely to make much headway towards 75% barring a significant change in the electorates attitudes towards PEDs.

About those wins: Regular readers know that I generally avoid dwelling upon pitcher win totals, because in this increasingly specialized era, they owe as much to adequate offensive, defensive, and bullpen support as they do to a pitchers own performance. While one neednt know how many wins Pettitte amassed in a season or a career to appreciate his true value, those totals have affected the popular perception of his career.

2021 BBWAA Candidate: Andy Pettitte

SOURCE: Baseball-Reference

Pettitte was born on June 15, 1972 in Baton Rouge, Louisiana. His father Tom, a police sergeant, built a mound in the familys back yard and began teaching his son by using a library book that showed how Nolan Ryan gripped his pitches. When Andy was eight, the family moved to Deer Park, Texas, a suburb of Houston, where Tom coached Andys teams right up until high school. Pettitte stood over six feet tall by his junior year at Deer Park High School, with a fastball in the low 80s and an advanced feel for mixing his pitches. By the time he was a senior, he stood 6-foot-5, but was pudgy enough to play center and nose tackle on the football team.

Though Pettitte received scholarship offers from Louisiana State University and other schools, the Yankees drafted him in the 22nd round in 1990. He did not sign, instead choosing to attend San Jacinto Junior College for a year, where he played for future Rice University coach Wayne Graham, who called him a left-handed Roger Clemens. The comparison resonated, for not only had Pettitte grown up idolizing Clemens, but Graham had coached the right-hander at San Jacinto in 1981. Graham helped transform Pettitte into a legitimate pitching prospect with a 91-93 mph fastball and better conditioning. The Yankees retained his rights up until a week before the 1991 draft, and ultimately landed him for an $80,000 bonus just before the signing deadline.

Pettitte split his first professional season (1991) between the Yankees Gulf Coast and New York-Penn League affiliates; at the latter stop, he crossed paths with Posada, also 19 years old and still primarily a second baseman. The pair spent 1992 together at A-level Greensboro of the South Atlantic League, where they were eventually joined by an 18-year-old Jeter, the Yankees 1992 first-round pick. At Greensboro, Pettitte posted a 2.20 ERA and 7.0 strikeouts per nine, and in each of his next two minor league seasons, he kept his ERAs near or below 3.00; he spent most of 1993 at High-A Prince William, with a taste of Double-A Albany-Colonie, where he returned for the start of 1994 before heading to Triple-A Columbus, where he posted a 2.98 ERA and a modest 5.7 strikeouts per nine.

In the spring of 1995, Pettitte placed 49th on Baseball Americas Top 100 prospects list, but lost the battle to be the Yankees fifth starter to Sterling Hitchcock and was sent to the bullpen; he made five relief appearances, briefly returned to Columbus, then joined the big clubs rotation when Jimmy Key suffered a shoulder injury that required surgery. He enjoyed a very solid rookie campaign, going 12-9 with a 4.17 ERA (111 ERA+) and 4.01 FIP in 175 innings en route to 2.9 WAR, helping the Yankees make the playoffs for the first time since 1981. Manager Buck Showalter gave him the ball to start Game 2 of the Division Series against the Mariners; Pettitte allowed two runs through six innings before being touched up for two more in the seventh, including the go-ahead run. The Yankees won the game in 15 innings but ultimately the lost series. The 23-year-old southpaw finished third in the AL Rookie of the Year voting, which was won by the Twins Marty Cordova.

Pettitte produced one of the biggest seasons of his career in 1996: 34 starts, 221 innings, a 3.87 ERA (129 ERA+), and an AL-high 21 wins, the last thanks to a robust 5.6 runs per game of offensive support. His 5.8 WAR ranked eighth in the AL. He did all of this while rotation-mate David Cone missed four months due to an aneurysm in his arm, Key served two DL stints, and Kenny Rogers scuffled. Pettitte made his first All-Star team and finished a very close second in the AL Cy Young race behind the Blue Jays Pat Hentgen, but not before helping the Yankees to their first championship in 18 years. After allowing four runs apiece in his Division and League Championship Series starts (both of which the Yankees won, 5-4) he delivered eight strong innings on three days rest in the ALCS Game 5 clincher against the Orioles. The Braves pounded him for seven runs in 2.1 innings in the World Series opener, but Pettitte rebounded to pitch 8.1 innings of five-hit shutout ball opposite 1996 NL Cy Young winner John Smoltz, a performance that in 2015 he called the best game of my career. The Yankees eked out a 1-0 victory and took a three-games-to-two series lead; they would win in six games.

Though he won only 18 games, Pettitte actually had a better season in 1997, when he made a league-high 35 starts and threw a career-high 240.1 innings with a 2.88 ERA (156 ERA+, both good for fourth in the league) and just seven homers allowed (a league-best 0.3 per nine). His 8.4 WAR ranked second in the league behind the Cy Young-winning Clemens, but he finished just fifth in the voting. He was lousy in the postseason, getting rocked for 11 runs in 11.2 innings by the Indians in his Division Series starts, both losses. It would be five years before the Yankees took such an early vacation in October again.

In three major league seasons, Pettitte had established himself as one of the games top starters, thanks in part to his development of a nasty cut fastball. His 16.9 WAR for the period ranked sixth in the majors from 1995-1997 behind only Greg Maddux, Clemens, Kevin Brown, Randy Johnson, and Pedro Martinez. Hed done it while pitching through a sore elbow, dating back to a three-inning relief stint in Baltimore on May 1, 1997, a day after getting torched for nine runs in one-plus inning. But whether it was his elbow or his over-reliance on his sinker-cutter combo at the expense of his curve and changeup, his performance took a significant step back even as the fate of the Yankees improved. From 1998-2000, while the Yankees won three straight championships, Pettitte averaged 32 starts and 204 innings, albeit with a 4.42 ERA (105 ERA+) and just a 1.53 strikeout-to-walk ratio, down from 2.21 for the three years prior. He was still good enough to average 2.8 WAR in that span, but the Yankees pondered trading him as he grew more expensive.

In July 1999, as the trade deadline loomed, the Yankees and Phillies neared a deal that would send Pettitte (then carrying a 5.65 ERA) to Philadelphia in exchange for three prospects including pitcher Adam Eaton and outfielder Reggie Taylor. In an organizational clash, Torre, pitching coach Mel Stottlemyre, and general manager Brian Cashman won out over owner George Steinbrenner and his cabal of Tampa-based advisors, who wanted to turn the rotation spot over to the immortal Ed Yarnall. Pettitte stayed, began working out with Clemens (who had been acquired in the spring) and allowed just three runs over his next four starts totaling 31 innings. That winter, he signed a three-year, $25.5 million extension with an $11.5 million club option for 2003.

As uneven as the 1998-2000 seasons were for Pettitte, he did place fourth in the AL Cy Young voting with the best of those years (2000: 19-9, 4.35 ERA, 3.6 WAR). During that stretch, he delivered eight quality postseason starts out of 11 with a combined 3.26 ERA; the Yankees went 10-1 in those starts, rallying to win even when he took early exits in Game 3 of the 1999 World Series against the Braves and Game 5 of the 2000 Division Series against the As. He threw seven shutout innings in Game 4 of the 1998 World Series against the Padres, helping the team complete a sweep, and made good starts in Games 1 and 5 in the 2000 Subway Series against the Mets. He left the latter tied at 2-2 through seven innings; the Yankees plated two runs in the ninth and Rivera closed it out for the teams third straight championship.

The work with Clemens began to rub off on Pettitte. In 2001, his fastball showed more zip, he worked inside more often, posted career-best strikeout and walk rates (7.4 and 1.8 per nine), brought his ERA below 4.00 (3.99) with a FIP nearly a run lower (3.02), and made his second All-Star team. He pitched well in his first three postseason starts agains the As and Mariners, allowing just five runs in 20.2 innings, and hung with the Diamondbacks Johnson for six innings in his World Series Game 2 start, entering the seventh trailing 1-0 before serving up a three-run homer to Matt Williams.

After losing the first two games in Arizona, the Yankees won three straight in New York to position themselves for their fourth straight title. Pettitte again took the ball opposite Johnson but was pummeled for six runs in two-plus innings; on ESPN Radios international broadcast, analyst Rick Sutcliffe noticed that he was tipping his pitches by double-pumping on every fastball from the stretch. The Yankees didnt discover the problem until it was too late; they lost both Game 6 and thanks to a two-run rally against Rivera Game 7 as well.

While elbow, back, and groin injuries sent Pettitte to the DL every year from 1999 through 2001, the 2002 season brought his first major injury, a bout of tendonitis that sidelined him for two months, from mid-April to mid-June. Limited to 22 starts, he nonetheless went 13-5 with a 3.27 ERA (135 ERA+ in 134.2 innings), and while he lasted just three innings in his lone postseason start against the Angels, the Yankees picked up his option that winter. Pettitte rewarded them with another strong, workhorse season, though his 21-8 record and 7.8 strikeouts per nine were flashier than the other numbers (4.02 ERA, 110 ERA+, 3.1 WAR, his fourth straight season between 3.1 and 3.6). In the best October showing of his career, he posted a 2.10 ERA in five starts, allowing more than two runs just once. He whiffed a postseason career high 10 Twins in his Division Series start, and came within one out of a shutout in Game 2 of the World Series before the Marlins plated an unearned run. Though he allowed just two runs (one earned) in seven innings in Game 6, Josh Beckett shut out the Yankees on five hits, giving the upstart Marlins a championship.

In December 2003, Pettitte shocked the baseball world by returning home to Texas. He did so by bypassing a three-year, $39 million offer from the Yankees in favor of a heavily backloaded, three-year, $31.5 million deal with the Astros. He wanted to go home to Houston, said Steinbrenner. And I admire him for wanting to be with his family. He couldnt do that in New York. He was a great competitor for me.

Soon joined in Houston by Clemens, whom hed coaxed out of retirement, Pettitte made just 15 starts in 2004 due to forearm woes that culminated in season-ending surgery to repair a torn flexor tendon. He returned better than ever in 2005, going 17-9 with a career-best 2.39 ERA (177 ERA+, with both marks second in the NL behind Clemens) and 6.8 WAR (fourth in the league). During one stretch in June and July, he allowed no more than one earned run in eight straight starts. His postseason performance wasnt great (4.26 ERA in 25.1 IP), as he wound up on the losing end three times while making four quality starts. The Astros, in their first World Series appearance, were swept by the White Sox.

Pettitte made a league-high 35 starts in his final year in Houston, but battled elbow tendonitis, and his ERA ballooned to 4.20 (106 ERA+), with his WAR dipping to 1.5. He had other problems as well. In October 2006, the Los Angeles Times published a report citing an affidavit from former Yankees pitcher Jason Grimsley, who alleged that both Pettitte and Clemens had used performance-enhancing drugs, and that he himself had obtained amphetamines, anabolic steroids, and human growth hormone from Brian McNamee, a former Yankees trainer who maintained a close working relationship with both pitchers. Pettitte vehemently denied the allegations, saying, Ive never used any drugs to enhance my performance on the baseball field before.

In December, the 34-year-old lefty agreed to return to the Yankees on a one-year, $16 million deal with a $16 million player option for 2008. On September 19, near the end of a typical season (15-9, 4.05 ERA, 5.9 K/9, 3.8 WAR), he beat the Orioles with a seven-inning, one-run performance to claim the 200th victory of his career. His 6.1 shutout innings against the Indians in Game 2 of the Division Series went for naught when Joba Chamberlain was devoured by a horde of midges.

Feeling the pull of family and mulling retirement, Pettitte declined his player option, mainly to allow the team to free up a roster spot while he deliberated. On December 3, he agreed to return at that same salary, but nine days later, his name was among the 89 included in the Mitchell Report. Two days later, he admitted to injecting HGH obtained through McNamee to recover from his 2002 elbow injury. In 2002 I was injured. I had heard that human growth hormone could promote faster healing for my elbow, he said in a statement released to the Associated Press. I felt an obligation to get back to my team as soon as possible. For this reason, and only this reason, for two days I tried human growth hormone. Though it was not against baseball rules, I was not comfortable with what I was doing, so I stopped.

Pettittes name remained in the headlines when Clemens appeared before Congress to challenge the findings pertaining to him in the report in February 2008. Pettitte said in a statement that Clemens had told him of using HGH nearly 10 years earlier, and that McNamee had told him that Clemens used steroids in 2003 or 04. Clemens claimed Pettitte misremembered.

On the field, Pettitte scuffled. While his 4.54 ERA was not a career worst, his 97 ERA+ was; it was the only time in his 18-year career that he allowed runs at a worse-than-average clip (his 3.71 FIP, his best in three years, told a different story). The Yankees missed the playoffs for the first time since the 1994 players strike, which triggered a major spending spree; $420 million worth of commitments brought Sabathia, A.J. Burnett, and Mark Teixeira to the Bronx. Pettitte, working on an incentive-laden one-year deal, served as a solid number three starter behind the two newcomers, rebounding to a 4.16 ERA and 3.4 WAR, then turned in one of his most memorable postseason runs. Though his overall 3.52 ERA in five starts totaling 30.2 innings wasnt remarkable, he joined the 2004 Red Soxs Derek Lowe by winning three clinching games in a single postseason, over the Twins (Division Series), Angels (ALCS), and Phillies (World Series).

While he made the AL All-Star team on the strength of an 11-2, 2.70 ERA first half, Pettittes 2010 was abbreviated by a groin strain that sidelined him for two months and limited him to just one September start longer than four innings. Nonetheless, he turned in a pair of seven-inning, two-run starts in the Yankees Division Series Game 2 victory over the Twins and their ALCS Game 3 defeat by the Rangers. Again deliberating on the retirement question, he pulled the plug in early February, just before pitchers and catchers reported.

Though he sat out all of 2011, Pettitte could not stay retired. In March 2012, the 39-year-old southpaw quietly agreed to return to the Yankees who had, in essence, left the light on for him on a $2.5 million deal. He returned to the majors on May 13, and pitched as well as ever (3.22 ERA, 9.1 K/9) until a one-hopper off the bat of the Indians Casey Kotchman fractured his left fibula. After missing nearly three months, he made a three-start September tuneup followed by a pair of good postseason starts totaling five runs allowed in 13.2 innings. Alas, he wound up on the short end both times, and the Yankees bowed to the Tigers in the ALCS.

Still hankering for more, Pettitte returned for his age-41 season, and for the first time since 2009 made 30 starts, finishing with a 3.74 ERA and 2.2 WAR in 185.1 innings. Unlike Rivera, who received a grand farewell tour that culminated with Jeter and Pettitte pulling him from his final appearance, Pettitte didnt announce his intentions until September 20, 2013. He threw seven innings of two-run ball against the Giants in his final Yankee Stadium start two days later, and then a complete-game five-hitter against the Astros in Houston, his home away from home, on September 28.

From a Hall of Fame standpoint, Pettittes claim rests on a high win total, very good run prevention after adjusting for his park and league, and a strong postseason resum, all of which are worth a closer look. First, the wins. Pettittes total of 256 ranks 42nd all-time, and is higher than 32 of the 65 enshrined starters, including Halladay (203), and 2018 Modern Baseball Era Committee honoree Jack Morris (254). However, 256 wins does not guarantee a spot in the Hall; there are eight pitchers with more on the outside looking in, including Clemens (354) and a pair of pitchers who spent more than a quarter-century in the majors, Tommy John (288) and Jim Kaat (283).

Wins, of course, are the product not just of a pitchers skill at run prevention but also of the support he receives from his offense, his defense, and his bullpen. In Pettittes case, prior to his original retirement he received offensive support that was about 10 percent better than the park-adjusted league average. Thats according to research done for the Baseball Prospectus book Extra Innings by Colin Wyers and myself in the fall of 2011, with said support for all starters defined simply as the runs scored on the day (or night) the starter pitched, and therefore available via game logs back into the 19th century. Wyers and I found just 12 Hall of Fame starters with better support, led by Chief Bender (117).

Pettitte was less well-supported by his defenses, in that he had a .312 career batting average on balls in play where the MLB average was .298; his FIP (3.74) is thus lower than his ERA (3.85). Bullpen support? Pettitte and Rivera the best ever at his job combined to set a record for teaming up, with Rivera saving 72 of Pettittes wins, far beyond the 57 wins of Oaklands Bob WelchDennis Eckersley combo.

Pettittes career ERA would be the second-highest in the Hall, in front of only Morris, but the adjustments for park and league are everything in this case. Pettitte has a 117-105 edge on Morris in ERA+. His 117 ERA+ matches that of Hall of Famer Gaylord Perry, who ranks 43rd among enshrined starters, and its two points better than Jim Bunning, Steve Carlton, Phil Niekro, Fergie Jenkins, and Eppa Rixey, who are tied for 45th. The problem for Pettitte is that all of those pitchers except Bunning threw at least 1,000 more innings.

Postseason-wise, the frequency of the Yankees participation in the three-tiered playoff format whose introduction coincided with the start of Pettittes career helped him set records for starts (44), innings (276.2) and wins (19, against 11 losses); meanwhile, hes fourth in strikeouts (183). While Pettitte certainly hit some high notes within that large body of work while helping the Yankees win five championships, he also had some duds, including seven starts with five or more runs allowed, only one of which went longer than five innings. His 3.81 postseason ERA is a ringer for his regular season mark; his 4.06 World Series ERA in 13 World Series starts (the second-highest total behind Whitey Fords 22) slightly worse; hes tied for seventh in World Series strikeouts (56) and eighth in innings (77.2) and wins (five). His ERA in his record 12 potential postseason series clinchers: 3.95 (the Yankees won eight); in four potential World Series clinchers: 3.68 (the Yankees won three). Cool stuff, but he was more like the second coming of Andy Pettitte than he was Schilling or Madison Bumgarner.

In terms of WAR, Pettittes career total of 60.2 is 13.1 WAR short of the standard at the position. Hes 64th 22 spots lower than his win total, remember and behind 44 of the 65 enshrined starters. Among those elected by the BBWAA, only Ford (57.1) and Catfish Hunter (40.9) threw at least 3,000 innings, where Dazzy Vance (60.1) and Bob Lemon (48.2) fell just short, with Sandy Koufax (48.9) short of 2,500 and Dizzy Dean (46.0) short of 2,000. Thats not a great argument in Pettittes favor.

Nor is the fact that his 34.1 peak score is tied with Rixey and Dutch Leonard for 170th. Pettittes 47.2 JAWS ranks 91st, ahead of only Ford (45.8), Dean (45.0), Lemon (43.5), and Herb Pennock (41.3) among BBWAA honorees. Of the currently active starters whose progress towards Cooperstown Ive been monitoring, hes well behind Justin Verlander, Zack Greinke, Clayton Kershaw, and Max Scherzer, as well as Sabathia, who retired last year.

Thus, based upon both traditional and advanced metrics, Pettitte would represent a rather weak choice for the Hall of Fame and I say that as somebody who had a considerable emotional investment in his career as a fan and would like nothing more than to find a rationale for electing him. I dont see one, and thats even while consigning his Mitchell Report-related transgressions to the Wild West era of the games drug problems, where if MLB couldnt punish him, I dont think voters should do so either.

Given all of that as well as the presence of two starters with stronger (albeit controversial) cases on the ballot in Clemens and Schilling, its tough to find a particularly compelling rationale to vote for Pettitte. Just 11.3% of voters did last year, and that was with ballot traffic clearing up considerably after back-to-back elections of four candidates. Voters using just 6.61 slots per ballot; they had ample space to include Pettitte, but did not.

Even with the elections of Mussina, Halladay, and perhaps Schilling pushing the door a bit more widely open for pitchers with fewer than 300 wins, Pettitte doesnt figure to follow, as he was not of their caliber in terms of run prevention, nor was he as decorated and celebrated except when it came to World Series rings (which isnt nothing). That said, it does appear as though Pettittes candidacy will persist, and although hes probably not a fit for Cooperstown, flags fly forever, and hell always be fondly remembered in the Bronx.

View original post here:
JAWS and the 2021 Hall of Fame Ballot: Andy Pettitte - FanGraphs

Nov 19

Human Growth Hormone (hGH) Market Top Key Players, Regions, Type and Application Outlook up-to 2020 to 2025 – The Daily Philadelphian

Eon Market Research has distributed the most recent statistical surveying report on Global Human Growth Hormone (hGH) Market. This report is prepared in a joint effort with the main top industry specialists and examination investigator group to give an endeavor completely market bits of knowledge and help them to settle on essential business choices. This report covers present market patterns, openings, challenges, and nitty-gritty serious examination of the business major parts in the market.

Human Growth Hormone (hGH) Market research study contains the wide-extending use of both primary and secondary data sources. The exploration cycle included the investigation of various variables that influence the business, including market condition, serious scene, past information, present patterns in the market, approaching advancements, and the specialized advancement in related industry, openings, market hindrances, and difficulties.

Request Free Sample Report:

**Note: Our Free Sample Report Offers a Short Outline of the Report, TOC, List of Tables and Figures, Competitive Landscape and Geographic Segmentation, Innovation and Future Developments Based on Research Methodology**

Top Key Players:

Eli Lilly and Company, Ferring Holding SA, Genentech, Merck and Co., Novo Nordisk, Pfizer, Sandoz International GmbH, Ipsen.

The report is an assortment of direct information, subjective and quantitative assessment by industry specialists, contributions from industry examiners and Human Growth Hormone (hGH) industry members over the worth chain. The report offers a top to bottom investigation of parent market patterns, macroeconomic measures, and control components. Besides, the report likewise overviews the subjective effect of unmistakable market factors on Human Growth Hormone (hGH) market sections and geologies.

Global Human Growth Hormone (hGH) Market: Regional Segments

The different section on regional segmentation gives the regional aspects of the worldwide Human Growth Hormone (hGH) market. This chapter describes the regulatory structure that is likely to impact the complete market. It highlights the political landscape in the market and predicts its influence on the Human Growth Hormone (hGH) market globally.

** The Middle East and Africa (GCC Countries and Egypt)

** North America (USA, Mexico, and Canada)

** South America (Brazil etc.)

** Europe (UK, Italy, France, Turkey, Germany, Russia, etc.)

Buy This Premium Report @

Segmentation By Type:

Recombinant Human Growth Hormone (rhGH)Human Growth Hormone (rhGH)

Segmentation By Application:

Growth Hormone DeficiencyTurner SyndromeIdiopathic Short StaturePrader-Willi SyndromeSmall for Gestational AgeOthers

The study objectives of this report are:

1. To break down worldwide Human Growth Hormone (hGH) status, future figure, development opportunity, key market and central members.

2. To deliberately profile the central participants and thoroughly break down their advancement plan and methodologies.

3. To characterize, portray and figure the market by type, market and key locales.

Some of the Major Highlights of TOC Covers:

1. Industry Overview.

2. Industry Environment (PEST Analysis).

2.1 Policy.

2.2 Economics.

2.3 Sociology.

2.4 Technology.

3. Human Growth Hormone (hGH) Market by Type.

4. Premium Insights.

5. Major Companies List.

6. Market Competition.

7. Demand by End Market.

7.1 Demand Situation.

7.2 Regional Demand Comparison.

7.3 Demand Forecast by 2020-2025.

7.4 Region Operation.

8. Sales Channel, Distributors, Traders and Dealers.

9. Research Findings and Conclusion.

10. Appendix.

Inquiry before Buying Human Growth Hormone (hGH) Market 2020 Report and Ask For Discount Here @

About Us:

Eon Market Research (EMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers.

Contact Us :

Eon Market Research

Phone: +1 703 879 7090

Email: [emailprotected]

See the original post:
Human Growth Hormone (hGH) Market Top Key Players, Regions, Type and Application Outlook up-to 2020 to 2025 - The Daily Philadelphian

Nov 19

2020 Current trends in Infrared Search and Track (IRST) System Market : Industry Overview by Size, Share, Future Growth, Development, Revenue, Top Key…

2020 Latest Report onInfrared Search and Track (IRST) SystemMarket

Los Angeles, United States,November2020:The report titled Global Infrared Search and Track (IRST) System Market is one of the most comprehensive and important additions to Alexareports archive of market research studies. It offers detailed research and analysis of key aspects of the global Infrared Search and Track (IRST) System market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global Infrared Search and Track (IRST) System market. Market participants can use the analysis on market dynamics to plan effective growth strategies and prepare for future challenges beforehand. Each trend of the global Infrared Search and Track (IRST) System market is carefully analyzed and researched about by the market analysts.

Infrared Search and Track (IRST) System Market competition by top manufacturers/ Key player Profiled: Leonardo, Thales Group, Rheinmetall AG, Lockheed Martin Corporation, Northrop Grumman Corporation, Aselsan A.S, HGH Systmes Infrarouges SAS, Safran, Tonbo Imaging Private Limited, Hughes Network Systems LLC

Get a PDF Sample Copy of the Report to understand the structure of the complete report:(Including Full TOC, List of Tables & Figures, Chart):

The global Infrared Search and Track (IRST) System Market is estimated to reach xxx million USD in 2020 and projected to grow at the CAGR of xx% during 2020-2026. According to the latest report added to the online repository of Alexareports the Infrared Search and Track (IRST) System market has witnessed an unprecedented growth till 2020. The extrapolated future growth is expected to continue at higher rates by 2026.

Infrared Search and Track (IRST) System Market Segment by Type covers: Scanning Head, Processing and Control Electronics, Display

Infrared Search and Track (IRST) System Market Segment by Application covers:Aerospace and Defense, Civil

After reading the Infrared Search and Track (IRST) System market report, readers get insight into:

*Major drivers and restraining factors, opportunities and challenges, and the competitive landscape*New, promising avenues in key regions*New revenue streams for all players in emerging markets*Focus and changing role of various regulatory agencies in bolstering new opportunities in various regions*Demand and uptake patterns in key industries of the Infrared Search and Track (IRST) System market*New research and development projects in new technologies in key regional markets*Changing revenue share and size of key product segments during the forecast period*Technologies and business models with disruptive potential

Based on region, the globalInfrared Search and Track (IRST) System market has been segmented into Americas (North America ((the U.S. and Canada),) and Latin Americas), Europe (Western Europe (Germany, France, Italy, Spain, UK and Rest of Europe) and Eastern Europe), Asia Pacific (Japan, India, China, Australia & South Korea, and Rest of Asia Pacific), and Middle East & Africa (Saudi Arabia, UAE, Kuwait, Qatar, South Africa, and Rest of the Middle East & Africa).

Key questions answered in the report:

What will the market growth rate of Infrared Search and Track (IRST) System market?What are the key factors driving the global Infrared Search and Track (IRST) System market size?Who are the key manufacturers in Infrared Search and Track (IRST) System market space?What are the market opportunities, market risk, and market overview of the Infrared Search and Track (IRST) System market?What are sales, revenue, and price analysis of top manufacturers of Infrared Search and Track (IRST) System market?Who are the distributors, traders, and dealers of Infrared Search and Track (IRST) System market?What are the Infrared Search and Track (IRST) System market opportunities and threats faced by the vendors in the global Infrared Search and Track (IRST) System industries?What are sales, revenue, and price analysis by types and applications of Infrared Search and Track (IRST) System market?What are sales, revenue, and price analysis by regions of Infrared Search and Track (IRST) System industries?

Get an Exclusive Discount on this report now at

Table of ContentsSection 1 Infrared Search and Track (IRST) System Product DefinitionSection 2 Global Infrared Search and Track (IRST) System Market Manufacturer Share and Market Overview2.1 Global Manufacturer Infrared Search and Track (IRST) System Shipments2.2 Global Manufacturer Infrared Search and Track (IRST) System Business Revenue2.3 Global Infrared Search and Track (IRST) System Market Overview2.4 COVID-19 Impact on Infrared Search and Track (IRST) System IndustrySection 3 Manufacturer Infrared Search and Track (IRST) System Business Introduction3.1 Leonardo Infrared Search and Track (IRST) System Business Introduction3.1.1 Leonardo Infrared Search and Track (IRST) System Shipments, Price, Revenue and Gross profit 2015-20203.1.2 Leonardo Infrared Search and Track (IRST) System Business Distribution by Region3.1.3 Leonardo Interview Record3.1.4 Leonardo Infrared Search and Track (IRST) System Business Profile3.1.5 Leonardo Infrared Search and Track (IRST) System Product Specification3.2 Thales Group Infrared Search and Track (IRST) System Business Introduction3.2.1 Thales Group Infrared Search and Track (IRST) System Shipments, Price, Revenue and Gross profit 2015-20203.2.2 Thales Group Infrared Search and Track (IRST) System Business Distribution by Region3.2.3 Interview Record3.2.4 Thales Group Infrared Search and Track (IRST) System Business Overview3.2.5 Thales Group Infrared Search and Track (IRST) System Product Specification3.3 Rheinmetall AG Infrared Search and Track (IRST) System Business Introduction3.3.1 Rheinmetall AG Infrared Search and Track (IRST) System Shipments, Price, Revenue and Gross profit 2015-20203.3.2 Rheinmetall AG Infrared Search and Track (IRST) System Business Distribution by Region3.3.3 Interview Record3.3.4 Rheinmetall AG Infrared Search and Track (IRST) System Business Overview3.3.5 Rheinmetall AG Infrared Search and Track (IRST) System Product Specification3.4 Lockheed Martin Corporation Infrared Search and Track (IRST) System Business Introduction3.5 Northrop Grumman Corporation Infrared Search and Track (IRST) System Business Introduction3.6 Aselsan A.S Infrared Search and Track (IRST) System Business IntroductionSection 4 Global Infrared Search and Track (IRST) System Market Segmentation (Region Level)4.1 North America Country4.1.1 United States Infrared Search and Track (IRST) System Market Size and Price Analysis 2015-20204.1.2 Canada Infrared Search and Track (IRST) System Market Size and Price Analysis 2015-20204.2 South America Country4.2.1 South America Infrared Search and Track (IRST) System Market Size and Price Analysis 2015-20204.3 Asia Country4.3.1 China Infrared Search and Track (IRST) System Market Size and Price Analysis 2015-20204.3.2 Japan Infrared Search and Track (IRST) System Market Size and Price Analysis 2015-20204.3.3 India Infrared Search and Track (IRST) System Market Size and Price Analysis 2015-20204.3.4 Korea Infrared Search and Track (IRST) System Market Size and Price Analysis 2015-20204.4 Europe Country4.4.1 Germany Infrared Search and Track (IRST) System Market Size and Price Analysis 2015-20204.4.2 UK Infrared Search and Track (IRST) System Market Size and Price Analysis 2015-20204.4.3 France Infrared Search and Track (IRST) System Market Size and Price Analysis 2015-20204.4.4 Italy Infrared Search and Track (IRST) System Market Size and Price Analysis 2015-20204.4.5 Europe Infrared Search and Track (IRST) System Market Size and Price Analysis 2015-20204.5 Other Country and Region4.5.1 Middle East Infrared Search and Track (IRST) System Market Size and Price Analysis 2015-20204.5.2 Africa Infrared Search and Track (IRST) System Market Size and Price Analysis 2015-20204.5.3 GCC Infrared Search and Track (IRST) System Market Size and Price Analysis 2015-20204.6 Global Infrared Search and Track (IRST) System Market Segmentation (Region Level) Analysis 2015-20204.7 Global Infrared Search and Track (IRST) System Market Segmentation (Region Level) AnalysisSection 5 Global Infrared Search and Track (IRST) System Market Segmentation (Product Type Level)5.1 Global Infrared Search and Track (IRST) System Market Segmentation (Product Type Level) Market Size 2015-20205.2 Different Infrared Search and Track (IRST) System Product Type Price 2015-20205.3 Global Infrared Search and Track (IRST) System Market Segmentation (Product Type Level) AnalysisSection 6 Global Infrared Search and Track (IRST) System Market Segmentation (Industry Level)6.1 Global Infrared Search and Track (IRST) System Market Segmentation (Industry Level) Market Size 2015-20206.2 Different Industry Price 2015-20206.3 Global Infrared Search and Track (IRST) System Market Segmentation (Industry Level) AnalysisSection 7 Global Infrared Search and Track (IRST) System Market Segmentation (Channel Level)7.1 Global Infrared Search and Track (IRST) System Market Segmentation (Channel Level) Sales Volume and Share 2015-20207.2 Global Infrared Search and Track (IRST) System Market Segmentation (Channel Level) AnalysisSection 8 Infrared Search and Track (IRST) System Market Forecast 2020-20258.1 Infrared Search and Track (IRST) System Segmentation Market Forecast (Region Level)8.2 Infrared Search and Track (IRST) System Segmentation Market Forecast (Product Type Level)8.3 Infrared Search and Track (IRST) System Segmentation Market Forecast (Industry Level)8.4 Infrared Search and Track (IRST) System Segmentation Market Forecast (Channel Level)Section 9 Infrared Search and Track (IRST) System Segmentation Product Type9.1 Scanning Head Product Introduction9.2 Processing and Control Electronics Product Introduction9.3 Display Product IntroductionSection 10 Infrared Search and Track (IRST) System Segmentation Industry10.1 Aerospace and Defense Clients10.2 Civil ClientsSection 11 Infrared Search and Track (IRST) System Cost of Production Analysis11.1 Raw Material Cost Analysis11.2 Technology Cost Analysis11.3 Labor Cost Analysis11.4 Cost OverviewSection 12 Conclusion

Buy this report now:

About Us:Alexa Reports is a globally celebrated premium market research service provider, with a strong legacy of empowering business with years of experience. We help our clients by implementing a decision support system through progressive statistical surveying, in-depth market analysis, and reliable forecast data.

Contact Us:Alexa ReportsPh no: +1-408-844-4624Email: [emailprotected]Site:

Visit link:
2020 Current trends in Infrared Search and Track (IRST) System Market : Industry Overview by Size, Share, Future Growth, Development, Revenue, Top Key...

Nov 17

What Can an HGH Deficiency Cost Adults in Terms of Their Overall Health and Well-Being? – News Anyway

Post Views: 130

For those who are perhaps not as familiar with the endocrine system, it is a group of glands that secrete hormones that allow the body to carry out a plurality of functions. For context, hormones play a crucial role when it comes to growth, particularly during childhood and adolescence, as well as respiration and metabolism. They also play an integral part in reproduction, sensory perception, and even movement. In total, the endocrine system consists of eight hormone-secreting glands, which include the following:

While all of the hormones-secreting glands in the body are important, the pituitary gland, which is responsible for secreting human growth hormones (HGH), is, arguably, the most important one among them.

What Is Human Growth Hormone in Adults?

Human growth hormones in adults are fundamentally the same as human growth hormones in children as the pituitary gland, which sits close to the hypothalamus, is the one responsible for secreting them in all human beings irrespective of age. For those not aware, the hypothalamus is the small region of the brain that acts as a connector between the nervous system and the endocrine system. During childhood and adolescence, HGH works alongside insulin-like growth factor 1 (IGF-1) to facilitate growth.

Also known as somatomedin C, insulin-like growth factor 1 is a hormone that regulates the secretion of HGH in the pituitary gland, which allows for the healthy growth and development of bones and tissue in the body. In adulthood, these same hormones are still very much important; however, during this time is when their role in the body slightly changes. Rather than focusing primarily on the healthy growth and development of bones and tissue, they become more involved in the things that aid in supporting good overall health, some of which include the following:

While we are on the topic, it should be noted that all of these things go a long way toward building muscle, burning fat, and boosting metabolism, all of which can make it easier for men and women to maintain a healthy weight.

Why Normal Levels of HGH Are Important Even in Adulthood

To better understand the importance of normal human growth hormone levels in adulthood, we should first take a look at what is considered optimal growth hormone levels for adult men and women. And to do that, we dont have to look too much further than an article published by MedlinePlus, a trusted health information resource and part of the U.S.

National Library of Medicine. The well-researched article noted that normal HGH levels for men should be somewhere in the neighborhood of 0.4 and 10 nanograms per milliliter. And as far as women go, between 1 and 14 nanograms per milliliter are said to fall within the range of normal HGH levels. Generally speaking, men and women with normal HGH levels are usually in better health than those who have HGH levels that are too low.

How Can a GH Deficiency Occur and What Costs Are Associated With It?

When adult men and women suffer a decline in growth hormone production that causes their growth hormone levels to fall too low, which is often a byproduct of getting older, most will develop what is known as a human growth hormone deficiency (HGHD). You can follow this link as a source of more detailed information about growth hormone therapy costs. A hormone deficiency of this kind can bring about an onslaught of unpleasant symptoms. Some of the more notable ones tend to include the following:

While aging is the most common cause of HGHD, it is by no means the only one. Studies show that any one of the following can also be a contributing factor for some individuals:

A GH deficiency can also be congenital or acquired, which means that they can exist even before birth.

Bottom Line

All in all, a growth hormone deficiency can cost adult men and women when it comes to their physical, mental, and even emotional health. Thankfully, there are prescription-based GH medications that can help boost low growth hormone levels and provided relief from most deficiency-related symptoms. Whats more, consuming a well-balanced diet and taking HGH-boosting dietary supplements can help in this regard as well. That said, if youre experiencing any of the symptoms commonly associated with a GH deficiency, it would be a good idea to speak with an endocrinologist as soon as possible.

Read more:
What Can an HGH Deficiency Cost Adults in Terms of Their Overall Health and Well-Being? - News Anyway

Nov 17

Baseball Hall of Fame: Controversial Picks Barry Bonds, Roger Clemens and Curt Schilling Lead 2021 Ballot –

The Baseball Writers' Association of America turned heads on Monday by releasing the 2021 National Baseball Hall of Fame ballot. There were 11 new names joining the 14 holdovers from the 2020 iteration, but three names drew particular attention. Barry Bonds, Roger Clemens and Curt Schilling headlined the list.

According to UPI, Schilling finished third behind Derek Jeter and Larry Walker last year, receiving 278 of 397 votes. These numbers gave him 70% of the vote, 20 shy of earning enshrinement. Clemens received 242 votes (61%) while Bonds had 241 (60.7%). These numbers fell shy of the required 75% for induction.

The all-time leader in home runs (762), Bonds also set the single-season record for homers with 73. He was a 14-time All-Star during his 22-year career but also faced allegations of steroid use. Bonds has remained out of the Hall of Fame and is running out of chances to hear his name.

"If they don't want me, just say you don't want me and be done with it," Bonds said about the Hall of Fame during an interview with The Athletic. "Just be done with it." Bonds will only be eligible for enshrinement for two more years. His name will be removed from the ballot following the 2022 vote.

Bonds never admitted to using steroids during his career. He reportedly told a grand jury that he used a substance that prosecutors say contain steroids. Federal prosecutors dropped the remaining charges against him in July 2015, ending a decades-long steroids case.

Similar to Bonds, Clemens faced allegations of steroid use in his career. He has strongly denied using steroids during his career. "I've been accused of something I'm not guilty of. ... I've never taken steroids or HGH," Clemens said during a congressional investigation into the use of banned substances.

While Bonds, Clemens and Schilling headline the list, there are 11 newcomers that face slim odds to be inducted. The list of newcomers includes: Mark Buehrle, A.J. Burnett, Michael Cuddyer, Dan Haren, LaTroy Hawkins, Tim Hudson, Torii Hunter, Aramis Ramirez, Nick Swisher, Shane Victorino and Barry Zito.

Unlike Bonds and Clemens, Schilling did not have steroid allegations. He instead sparked debates with his comments as an analyst and on social media. For example, he posted a meme comparing the percentage of extremists among Muslims and 1940s Germans. He has also made several comments in the past about the Clintons, Benghazi and the North Carolina "bathroom bill."

Voting for the Baseball Hall of Fame will be announced on Jan. 26, providing answers about some of the sport's biggest names and their legacies. If anyone receives the required 75% of the vote, they will be inducted on July 25 alongside Jeter and Walker. The two men were voted into the Hall of Fame in 2020 but had to wait one year for their ceremony due to the COVID-19 pandemic.

Read the original here:
Baseball Hall of Fame: Controversial Picks Barry Bonds, Roger Clemens and Curt Schilling Lead 2021 Ballot -

Nov 13

Should Heartland Group Holdings Limited (NZSE:HGH) Be Part Of Your Dividend Portfolio? – Simply Wall St

Today well take a closer look at Heartland Group Holdings Limited (NZSE:HGH) from a dividend investors perspective. Owning a strong business and reinvesting the dividends is widely seen as an attractive way of growing your wealth. If you are hoping to live on your dividends, its important to be more stringent with your investments than the average punter. Regular readers know we like to apply the same approach to each dividend stock, and we hope youll find our analysis useful.

With a eight-year payment history and a 5.2% yield, many investors probably find Heartland Group Holdings intriguing. It sure looks interesting on these metrics but theres always more to the story. There are a few simple ways to reduce the risks of buying Heartland Group Holdings for its dividend, and well go through these below.

Explore this interactive chart for our latest analysis on Heartland Group Holdings!

Dividends are typically paid from company earnings. If a company pays more in dividends than it earned, then the dividend might become unsustainable hardly an ideal situation. As a result, we should always investigate whether a company can afford its dividend, measured as a percentage of a companys net income after tax. Heartland Group Holdings paid out 56% of its profit as dividends, over the trailing twelve month period. A payout ratio above 50% generally implies a business is reaching maturity, although it is still possible to reinvest in the business or increase the dividend over time.

Consider getting our latest analysis on Heartland Group Holdings financial position here.

Before buying a stock for its income, we want to see if the dividends have been stable in the past, and if the company has a track record of maintaining its dividend. Looking at the last decade of data, we can see that Heartland Group Holdings paid its first dividend at least eight years ago. Its good to see that Heartland Group Holdings has been paying a dividend for a number of years. However, the dividend has been cut at least once in the past, and were concerned that what has been cut once, could be cut again. During the past eight-year period, the first annual payment was NZ$0.04 in 2012, compared to NZ$0.07 last year. This works out to be a compound annual growth rate (CAGR) of approximately 7.2% a year over that time. The growth in dividends has not been linear, but the CAGR is a decent approximation of the rate of change over this time frame.

Its good to see the dividend growing at a decent rate, but the dividend has been cut at least once in the past. Heartland Group Holdings might have put its house in order since then, but we remain cautious.

With a relatively unstable dividend, its even more important to see if earnings per share (EPS) are growing. Why take the risk of a dividend getting cut, unless theres a good chance of bigger dividends in future? Heartland Group Holdings has grown its earnings per share at 3.9% per annum over the past five years. 3.9% per annum is not a particularly high rate of growth, which we find curious. When a business is not growing, it often makes more sense to pay higher dividends to shareholders rather than retain the cash with no way to utilise it.

When we look at a dividend stock, we need to form a judgement on whether the dividend will grow, if the company is able to maintain it in a wide range of economic circumstances, and if the dividend payout is sustainable. First, we think Heartland Group Holdings has an acceptable payout ratio. Second, earnings growth has been ordinary, and its history of dividend payments is chequered having cut its dividend at least once in the past. While were not hugely bearish on it, overall we think there are potentially better dividend stocks than Heartland Group Holdings out there.

Companies possessing a stable dividend policy will likely enjoy greater investor interest than those suffering from a more inconsistent approach. However, there are other things to consider for investors when analysing stock performance. For example, weve picked out 1 warning sign for Heartland Group Holdings that investors should know about before committing capital to this stock.

Looking for more high-yielding dividend ideas? Try our curated list of dividend stocks with a yield above 3%.

PromotedWhen trading Heartland Group Holdings or any other investment, use the platform considered by many to be the Professionals Gateway to the Worlds Market, Interactive Brokers. You get the lowest-cost* trading on stocks, options, futures, forex, bonds and funds worldwide from a single integrated account.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. *Interactive Brokers Rated Lowest Cost Broker by Annual Online Review 2020

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email

Excerpt from:
Should Heartland Group Holdings Limited (NZSE:HGH) Be Part Of Your Dividend Portfolio? - Simply Wall St

Nov 13

Increase in the Adoption of Hormone Replacement Therapy to Propel the Growth of the Hormone Replacement Therapy Market Between 2020-2027 – PRnews…

Final Report will add the analysis of the impact of COVID-19 on this industry.

November 2020:

The global Hormone Replacement Therapy Market research report offers all the vital data in the domain. The latest report assists new bees as well as established market participants to analyze and predict the Hormone Replacement Therapy market at the regional as well as global level. It covers the volume [k MT] as well as revenues [USD Million] of the global Hormone Replacement Therapy market for the estimated period. Numerous key players Novartis AG, Abbott Laboratories, Mylan N.V., Merck KgaA, Bayer AG, Pfizer Inc., Novo Nordisk A/S, QuatRx Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Amgen, Inc., and Eli Lilly and Company. are dominating the global Hormone Replacement Therapy market. These players hold the majority of share of the global Hormone Replacement Therapy market.

DownloadSamplecopy + All Related Graphs & Charts @:

The data presented in the global Hormone Replacement Therapy market offers budding opportunities, which help users to make strategic moves and prosper their business. The report highlights the impact of numerous factors that might result in obstructing or propelling the Hormone Replacement Therapy market at global as well as local level. The global Hormone Replacement Therapy market research report offers the summary of key players dominating the market including several aspects such as their financial summary, business strategy, and most recent developments in these firms.

Detailed Segmentation:

By Therapy Type:Estrogen Replacement TherapyHuman Growth Hormone (HGH) Replacement TherapyThyroid Replacement TherapyTestosterone Replacement TherapyGlobal Hormone Replacement Therapy Market, By Route of Administration:OralParenteralOthersGlobal Hormone Replacement Therapy Market, By Application:HypothyroidismMale HypogonadismGrowth Hormone DeficiencyMenopauseOthers

By Region

North America (U.S., Canada, Mexico)

Asia Pacific (India, China, Japan, South Korea, ASEAN, Rest of Asia Pacific)

Europe (Italy, Germany, France, Spain, Central & Eastern Europe, Rest of Europe)

Middle East & Africa (GCC, Turkey, Rest of the Middle East & Africa)

South America (Brazil, Argentina, Rest of South America)

The study encompasses profiles of major companies operating in the Hormone Replacement Therapy Market. Key players profiled in the report includes: Novartis AG, Abbott Laboratories, Mylan N.V., Merck KgaA, Bayer AG, Pfizer Inc., Novo Nordisk A/S, QuatRx Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Amgen, Inc., and Eli Lilly and Company.

Key points of the global Hormone Replacement Therapy market

The oretical analysis of the global Hormone Replacement Therapy market stimulators, products, and other vital facets

Recent, historical, and future trends in terms of revenue and market dynamics are reported

Pin-point analysis of the competitive market dynamics and investment structure is predicted to grow

Future market trends, latest innovations, and various business strategies are reported

Market dynamics include growth influencers, opportunities, threats, challenges, and other crucial facets

The global Hormone Replacement Therapy market research report offers users with an all-inclusive package of market analysis that includes current market size, expansion rate, and value chain analysis. The global Hormone Replacement Therapy market is segmented on a regional basis Europe, North America, Latin America, Asia Pacific, and Middle East & Africa as well. To offer a comprehensive view and competitive outlook of the global Hormone Replacement Therapy market, our review team employs numerous methodological procedures, for instance, Porters five forces analysis.

This research report includes the analysis of various Hormone Replacement Therapy market segments. The bifurcation of the global market is done based on its present and prospective inclinations. The regional bifurcation involves the present market scenario in the region along with the future projection of the global Hormone Replacement Therapy market. The global market report offers an overview of expected market conditions due to changes in the technological, topographical, and economic elements.

Need a discount?

Note: *The discount is offered on the Standard Price of the report.

Ask for the discount @

Questions answered in the report include

What is the expected market size by the end of the forecast period?

What are the major factors initiating the global Hormone Replacement Therapy market growth?

What are the latest developments and trending market strategies that are influencing the growth of the Hormone Replacement Therapy market?

What are the key outcomes of the Hormone Replacement Therapy market developments?

Who are the key players in the market?

What are the opportunities and challenges faced by the key players?

Key Reasons for Purchasing Global Hormone Replacement Therapy Market Report

New approaches and latest development trend that describe the structure of the market

Advanced market breakdown structure

Historical data and future market scope

In-depth market analysis based on statistics, growth stimulators, and market developments

Statistical data representation through figurative, numerical, and theoretical elaboration

Report provides insight of the business and sales activities

Why Coherent Market Insights:

Explore extensive library of market reports

Accurate and Actionable insights

Focus on Key Trends and Market Movements

Critical Consulting Project Execution

24/7 Online and Offline Support

Most-detailed market segmentation

Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations

Promo-code: CMIFIRST1000

Buy This Complete A Business Report @:

NOTE:Our team is studying Covid-19 and its impact on various industry verticals and wherever required we will be considering Covid-19 footprints for a better analysis of markets and industries. Cordially get in touch for more details

Interested about who is winning the race of COVID-19 Vaccine. Coherent Market Insights (CMI)

providesCOVID-19 Vaccine Trackerfor all the latest updates about COVID-19 Vaccine.

Customization of the Report:

If you do not think that you are looking into Artificial Pancreas Device Systems report or need any clear preconditions, please contact our custom research team at([emailprotected])

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:Mr. ShahCoherent Market Insights1001 4th Ave,#3200Seattle, WA 98154Tel: +1-206-701-6702Email: [emailprotected]

See the original post:
Increase in the Adoption of Hormone Replacement Therapy to Propel the Growth of the Hormone Replacement Therapy Market Between 2020-2027 - PRnews...

Page 4«..3456..1020..»